Flt4 is a receptor protein tyrosine kinase that is expressed in the adult lymphatic endothelium and high endothelial venules. We have used a BIAcore assay to identify rodent and human cell conditioned media containing the ligand of Flt4 (Flt4-L). Receptor-based anity chromatography was used to purify this growth factor, followed by amino acid sequencing and molecular cloning of the murine cDNA, the orthologue of human vascular endothelial growth factor-C and vascular endothelial growth factor related protein. The murinē t4-L gene was localized to chromosome 8 and demonstrated to be widely expressed. Flt4-L was found to have a hydrophobic signal sequence and a pro-peptidelike sequence that is removed to generate the mature Nterminus. In addition, the C-terminal region of Flt4-L has four repeats of a cysteine-rich motif that is presumably also proteolytically processed to generate the 21 000 M r polypeptide subunit of the Flt4-L homodimer. Recombinant Flt4-L activated Flt4 as judged by induction of tyrosyl phosphorylation, and induced mitogenesis in vitro of lymphatic endothelial cells.
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To identify a source of the Flt4 ligand, we used a Flt4-Fc fusion protein. This consists of the extracellular region of murine Flt4 (Finnerty et al., 1993) fused to the hinge-C H 2-C H 3 domains of human immunoglobulin g1. The conditioned media (CM) of over 100 dierent cell lines were screened for binding to Flt4-Fc using a BIAcore 2000 instrument. The media conditioned by the murine embryonic liver cell line, BNL 1NG A.2, human bladder carcinoma 5637, and bualo rat BRL 3A each showed binding to Flt4-Fc, but not human IgG1 (Figure 1 ). The binding was speci®c because when the CM was coinjected with excess Flt4-Fc, but not human IgG1 or KIT-Fc, the signal was inhibited (Figure 1 ). The presence of Flt4 ligand (Flt4-L) in BNL 1NG A.2 CM was con®rmed by demonstrating that it activated the Flt4 receptor protein tyrosine kinase. CHO cells stably transfected with a murine Flt4 cDNA expression vector were treated with 50-fold concentrated BNL 1NG A.2 CM for 10 min at 378C. This resulted in a marked increase in tyrosyl phosphoryla- Six micrograms of Flt4-L were puri®ed from 15L of BNL 1NG A.2 CM using Flt4-Fc anity chromatography. Flt4-Fc (100 mg/ml) or KIT-Fc (200 mg/ml) were directly immobilized to 1 mL Pharmacia HiTrap NHS columns. A volume of 50 ml of concentrated BNL 1NG A.2 CM was loaded ®rst onto the KIT-Fc column to adsorb nonspeci®c binding, then onto the Flt4-Fc column. The columns were washed and separately eluted with 24 mM hydrochloric acid. As expected, only fractions from the Flt4-Fc anity column had binding to Flt4-Fc on the BIAcore assay. The speci®c activity in response units (RU)/mg was determined using RU that were in the linear range of RU versus concentration of Flt4-L puri®cation fractions. The speci®c activity of Flt4-L from BNL 1NG A.2 was 4.2610 6 RU/mg, an increase of 98 455-fold after the Flt4-Fc receptor anity column step.
When the puri®ed fractions from the Flt4-Fc column were analysed by reducing SDS ± PAGE, three polypeptides were shown to correlate with the Flt4-Fc binding activity. All three species were puri®ed by Flt4-Fc column chromatography from several dierent preparations of BNL 1NG A.2 medium. These polypeptides were approximately 21 000, 32 000 and 37 000 M r (Figure 2b ). The Nterminal sequences of the 21 000 and 32 000 M r species were determined by Edman degradation on an ABI 492 sequencer and found to be identical: AHYNTEILKSIDNEWRKTQ.
To determine if the three polypeptides associate, we analysed an iodinated sample of the puri®ed protein by two dimensional non-reducing versus reducing SDS ± PAGE. Several multimeric forms of Flt4-L were discovered by this analysis (data not shown). The reduced 21 000 M r polypeptide forms an apparent homodimer that migrates at approximately 40 000 M r under nonreducing conditions. This species was also associated with the 32 000 and 37 000 M r polypeptides and forms an apparent multimer. We presume this is the same 21 000 M r polypeptide since no other sequences were detected during N-terminal or later tryptic sequence analysis (data not shown).
On the basis of the N-terminal amino acid sequence obtained from both the 21 000 and 32 000 M r bands, two degenerate oligonucleotide primers for the polymerase chain reaction (PCR) were designed. The forward primer was based on`HYNTEI' (128-fold degenerate) and the reverse primer was based on `NEWRKT' (64-fold degenerate). The ampli®cation product of this PCR was predicted to be 65 bp with a novel 16 bp separating the two primer positions. This PCR was performed on ten pools of a BNL 1NG A.2 cDNA expression library containing approximately 11 000 transformants each. A product of the expected size was found in one pool (#6) (data not shown). This pool was subdivided in a series of steps using this diagnostic PCR assay to follow enrichment of the desired cDNA. A single positive plasmid (J7) was identi®ed and the nucleotide sequence of its 1804 bp insert determined.
The J7 cDNA sequence was found to contain an open reading frame that encodes a polypeptide of 415 residues ( Figure 3 ). This deduced amino acid sequence includes an exact match to the N-terminal sequence determined (residues 112 ± 130; underlined in Figure  3 ), thereby con®rming that this cDNA encodes the Flt4-Fc binding protein. This murine Flt4-L sequence has a short hydrophobic stretch of 15 residues that may function as a signal sequence. An additional 92 residues are found between the predicted signal sequence cleavage and the known N-terminal sequence of the 21 000 and 32 000 M r forms. Thus, Flt4-L may undergo additional proteolytic processing to form the mature polypeptide product. Murine Flt4-L was found to have homology with the vascular endothelial cell growth factor (VEGF) family of growth factors. In particular, the eight cysteine residues that have conserved positions in plateletderived growth factors, VEGF, placental growth factor (PlGF) and VEGF-B, are each found in murine Flt4-L (Figure 3, in bold) .
In the region between the ®rst (residue 131) and last (residue 211) of these eight conserved cysteines, the Flt4-L has an identity (and similarity) to murine VEGF of 37% (56%), murine PlGF of 30% (48%) and murine VEGF-B of 36% (57%). In contrast to VEGF and PlGF, murine Flt-L was found to have a long, C-terminal extension that contained four repeats of a cysteine-rich motif, C(X) 10 CXCXC. A single copy of this sequence was also found in the C-terminal sequences of VEGF and VEGF-B, but both lacked the ®rst cysteine residue of the consensus motif.
We also isolated a human FLT4-L cDNA from the human 5637 cell line ( Figure 3 ) and found it to be essentially identical to the nucleotide sequences described previously for VEGF-C and VEGF-related protein (VRP) Lee et al., 1996) . It shows 85% nucleotide identity and 86% amino acid identity to the murine¯t4-L cDNA. Joukov et al. (1996) reported the N-terminus of human VEGF-C to be at residue 103 (as depicted in Figure 3 ), in contrast to our ®nding that residue 112 is the N-terminus of the murine polypeptide. This may be a dierence between species or indicate a variation in processing or alternative splicing.
The expression of murine Flt4-L cDNA was studied in transiently transfected COS-1 cells. After biosynthetically labelling with L-[ 3 5 S]methionine and L- Three labelled polypeptides were found to be precipitated from the CM of Flt4-L expressing cells and not from mock transfected cells (Figure 2c ). These polypeptides of approximately 21 000, 32 000 and 37 000 M r closely resembled the three species puri®ed from BNL 1NG A.2 CM by Flt4-Fc anity chromatography. It is presumed that the 37 000 M r polypeptide results from cleavage at residue 112, and one or more proteolytic cleavages are necessary to generate the other two forms.
The functional activity of the recombinant murine Flt4-L was tested in the CHO/Flt4 receptor activation assay. Flt4-L puri®ed from COS-1 CM by Flt4-Fc binding was used to activate Flt4, resulting in a stimulation of Flt4 tyrosyl phosphorylation ( Figure  2a, lane 3) . Elution fractions not containing Flt4-Fc binding activity in the BIAcore assay did not stimulate phosphorylation (Figure 2a, lane 4) . The blot ®lter was stripped and reprobed with antisera against Flt4 to con®rm equivalent amounts of receptor polypeptide in each immunoprecipitation (Figure 2a, lower panel) .
The expression of the¯t4-L gene was examined by Northern blot analysis of a range of primary murine tissue RNAs. A transcript of approximately 2.6 kb was found in all tissues, with a smaller transcript of approximately 2.1 kb in a subset of tissues ( Figure  4a) . A duplicate blot was probed with an¯t4 cDNA probe. An approximately 7.0 kb transcript was detected in spleen RNA, with lower levels in other tissue RNAs including lung and kidney (Figure 4b ). No¯t4 expression was detected in brain. Expression of the human FLT4-L was examined in a range of human immune tissue RNAs. Transcripts were detected in spleen, lymph node, thymus, appendix, bone marrow and fetal liver, but not in peripheral blood lymphocytes (Figure 4c ). The majority of these human RNAs showed two FLT4-L transcripts. However, a third larger transcript was noted in appendix RNA. A single open reading frame has been found in the murine and human cDNAs reported in this work and by others. Further work is needed to characterize the mechanisms responsible for these dierent transcripts.
Single strand conformation polymorphism (SSCP) analysis was used to map¯t4-L (Beier, 1993) . Primers corresponding to the 3' untranslated region of¯t4-L were analysed and found to identify an SSCP between C57BL/6J and Mus spretus (5'-dATCTGAACTAA-GATCATACCAGT-3' and 5'-dGCACATGAGTGC-CAGTCCTC-3'; 948C, 1 min; 558C, 1 min; 728C, (Claey et al., 1992) , PlGF (GenBank X80171) and VEGF-B (Olofsson et al., 1996) . The murine and human¯t4-L cDNA sequences have been deposited with GenBank (accession nos. U58112 and U58111). The N-terminal amino acid sequence determined experimentally for murine Flt4-L is shown underlined. The putative signal peptide cleavage position is shown with an arrowhead (von Heijne, 1987) . Conserved residues are boxed, and the eight cysteine residues that are conserved in each of these growth factors are shown in bold. The position of putative N-linked glycosylation sites in Flt4-L are each shown with an asterisk. The CX 10 CXCXC repeats are each shown reverse shaded. Individual pools of transformants were screened for the murine¯t4-L cDNA using a PCR and two degenerate oligonucleotide primers: 5'-d CAGAATTCR G, C or T; R=A or G; Y=C or T; K=G or T) . The eight bases at the 5' end of each primer were added to introduce a restriction site. Ampli®cation with Taq DNA polymerase (Gibco BRL, Gaithersburg, MD) was performed in a Gene Amp 9600 thermal cycler (Perkin Elmer, Norwalk, CT), for three cycles at 968C, 8 s; 348C, 15 s and 728C, 5 s; and 30 cycles at 968C, 8 s; 458C, 15 s; and 728C, 10 s. The PCRs were examined by polyacrylamide gel electrophoresis (Novex, San Diego, CA) and ethidium bromide staining 2 min, for 40 cycles with a ®nal extension at 728C). The BSS inter-speci®c backcross was genotyped and the strain distribution pattern analysed using the MAP Manager program (Rowe et al., 1994; Manley, 1991) . The¯t4-L gene was found to map to chromosome 8 with a LOD likelihood score of 27.1. It was nonrecombinant with the micro-satellite markers D8Mit6 (0/90 progeny) and is 1.1+1.1 cM distal to the muscle adenine nucleotide translocator gene, Ant 1 (1 recombinant/89 progeny). This locus has been mapped to human chromosome 4q35 (Fan et al., 1992) . Since subchromosomal linkage relationships are conserved in many cases between mouse and man, this result suggests that the human FLT4-L gene will be found in this region.
Adult human expression of FLT4-L has been reported to be restricted to the lymphatic endothelium and some high endothelial venules (Kaipainen et al., 1995) . We tested the mitogenic action of Flt4-L on lymphatic endothelial cells (LECs) isolated from sheep mesenteric lymphatic vessels and grown in culture. The isolation and growth of these cells and the confirmation of the homogeneity of these cultures as lymphatic endothelium by morphological and immunocytochemical methods was as described previously (Leak and Jones, 1993, 1994) . Cultures were used for assays at passages 3 ± 6 and all experiments were performed in triplicate. Con¯uent, quiescent monolayers of LECs on glass cover slips were stimulated with 100 ng/ml of puri®ed, murine Flt4-L produced in COS cells or human rVEGF. After 12 h of stimulation, cells were labelled with 20 mM 5-bromo-2'-deoxyuridine (BrdU), and 10 mM 5-¯uoro-2'-deoxyuridine to block intracellular thymidylate synthase activity, for an additional 7 h. Nuclei incorporating BrdU were labelled with antiBrdU monoclonal antibody and anti-murine IgGperoxidase, and visualized with 3,3'diaminobenzidine. Ten ®elds were analysed for each slide using 206 objective, and the mean number of labeled nucleic was determined as a percentage of the total number of nuclei+standard error of the mean. In the absence of growth factor, BrdU incorporated into approximately 32.7+1.92% of cell nuclei. There was a signi®cant increase in the number of labelled nuclei after treatment with rFlt4-L (84.5+2.5%; P40.001) or rVEGF (70.4+2.26%; P40.001). This stimulation was comparable to that found by addition of the endothelial cell growth supplement used to routinely culture the LECs. Future work will address the speci®c roles of FLT4-L in lymphangiogenesis.
